Reuters logo
BRIEF-Abbvie says two phase 3 studies evaluating veliparib did not meet their primary endpoints
April 19, 2017 / 10:06 PM / 7 months ago

BRIEF-Abbvie says two phase 3 studies evaluating veliparib did not meet their primary endpoints

April 19 (Reuters) - Abbvie Inc:

* Abbvie announces topline results from two phase 3 studies investigating veliparib in combination with chemotherapy for the treatment of patients with advanced or metastatic squamous non-small cell lung cancer and early-stage triple-negative breast cancer

* Abbvie inc - two phase 3 studies evaluating veliparib did not meet their primary endpoints Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below